Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions

Annals of the Rheumatic Diseases
Naomi SchlesingerAlexander K So

Abstract

Gouty arthritis patients for whom non-steroidal anti-inflammatory drugs and colchicine are inappropriate have limited treatment options. Canakinumab, an anti-interleukin-1β monoclonal antibody, may be an option for such patients. The authors assessed the efficacy/safety of one dose of canakinumab 150 mg (n=230) or triamcinolone acetonide (TA) 40 mg (n=226) at baseline and upon a new flare in frequently flaring patients contraindicated for, intolerant of, or unresponsive to non-steroidal anti-inflammatory drugs and/or colchicine. Core study co-primary endpoints were pain intensity 72 h postdose (0-100 mm visual analogue scale and time to first new flare. Two 12-week randomised, multicentre, active-controlled, double-blind, parallel-group core studies with double-blind 12-week extensions (response in acute flare and in prevention of episodes of re-flare in gout (β-RELIEVED and β-RELIEVED-II)). 82.6% patients had comorbidities. Mean 72-h visual analogue scale pain score was lower with canakinumab (25.0 mm vs 35.7 mm; difference, -10.7 mm; 95% CI -15.4 to -6.0; p<0.0001), with significantly less physician-assessed tenderness and swelling (ORs=2.16 and 2.74; both p≤0.01) versus TA. Canakinumab significantly delayed time to first new...Continue Reading

Citations

Jan 25, 2013·Seminars in Immunopathology·Ioannis MitroulisKonstantinos Ritis
May 8, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Katherine A Lyseng-Williamson
Mar 8, 2013·Current Opinion in Rheumatology·Leslie Harrold
Jan 17, 2014·Arthritis Research & Therapy·Sébastien OttavianiPhilippe Dieudé
Jan 16, 2014·Annual Review of Medicine·Adriana A Jesus, Raphaela Goldbach-Mansky
Jan 11, 2014·Current Rheumatology Reports·Naomi Schlesinger
Nov 28, 2013·Seminars in Immunology·Charles A Dinarello, Jos W M van der Meer
Mar 1, 2014·Der Internist·U Müller-Ladner, U Lange
May 24, 2013·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Monika Moll, Jasmin B Kuemmerle-Deschner
Mar 13, 2014·Nature Reviews. Rheumatology·Frances ReesMichael Doherty
May 24, 2014·Nature Reviews. Drug Discovery·Marc Y Donath
Jan 19, 2013·Annual Review of Medicine·Daria B Crittenden, Michael H Pillinger
Mar 22, 2014·Seminars in Arthritis and Rheumatism·Puja P KhannaDinesh Khanna
Aug 20, 2014·Nature Reviews. Rheumatology·Pascal RichetteThomas Bardin
Apr 25, 2014·Rheumatology·Augustin LatourtePascal Richette
Dec 31, 2014·Expert Opinion on Pharmacotherapy·Philip C Robinson, Nicola Dalbeth
Jan 24, 2014·Expert Review of Clinical Immunology·Fernando Perez-RuizAna María Herrero-Beites
May 3, 2013·Current Medical Research and Opinion·L Punzi, A So
Apr 8, 2014·Rheumatic Diseases Clinics of North America·Ashika Chhana, Nicola Dalbeth
Apr 8, 2014·Rheumatic Diseases Clinics of North America·Naomi Schlesinger
Dec 1, 2012·Joint, Bone, Spine : Revue Du Rhumatisme·Dimitrios DaoussisAndrew P Andonopoulos
Nov 21, 2012·Joint, Bone, Spine : Revue Du Rhumatisme·Alexander So, Nathalie Busso
Oct 24, 2012·Advances in Chronic Kidney Disease·John S Sundy
Jan 1, 2016·Joint, Bone, Spine : Revue Du Rhumatisme·Thomas Bardin
Nov 10, 2014·Immunologic Research·Carlo SelmiCarlo A Sciré
Feb 20, 2013·Orthopaedic Surgery·Zhen-hua Fang, Hazibullah Waizy
Oct 15, 2013·Journal of Clinical Pharmacology·Abhijit ChakrabortyDan Howard
May 7, 2014·Annals of the Rheumatic Diseases·P RichetteT Bardin
Sep 1, 2015·Clinics in Dermatology·Bediha Bölükbasi, Karoline Krause
Aug 27, 2015·Progress in Transplantation : Official Publication, North American Transplant Coordinators Organization ... [et Al.]·Peter M SullivanEric M Tichy
Apr 18, 2016·Joint, Bone, Spine : Revue Du Rhumatisme·Frédéric Lioté
Aug 13, 2015·Best Practice & Research. Clinical Rheumatology·R RamondaL Punzi
Mar 12, 2015·Orphanet Journal of Rare Diseases·Linda Rossi-SemeranoUNKNOWN MAIL1 (Maladies Auto-inflammatoires et Anti-IL-1) study Group on behalf of CRI (Club Rhumatisme et Inflammation)
Mar 25, 2015·Rheumatology International·Qiong-Yao Gong, Yong Chen
May 20, 2014·BioMed Research International·L Cavagna, W J Taylor
Feb 11, 2015·Pulmonary Pharmacology & Therapeutics·Paola RoglianiMaria Gabriella Matera
Apr 17, 2015·Pharmacogenomics·Rebecca L Roberts, Lisa K Stamp
Apr 22, 2016·Current Rheumatology Reports·Robert T Keenan, Naomi Schlesinger
Apr 16, 2014·Clinical Rheumatology·Antonio VitaleMauro Galeazzi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.